Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction
Background There are no effective therapies to prevent the occurrence and progression of vertebrobasilar dolichoectasia (VBD). In this study, we investigated the relationship between serum levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) and the occurrence and progression of VBD. Methods...
Gespeichert in:
| Veröffentlicht in: | Neurological sciences 2021-02, Vol.42 (2), p.599-605 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 605 |
|---|---|
| container_issue | 2 |
| container_start_page | 599 |
| container_title | Neurological sciences |
| container_volume | 42 |
| creator | Liu, Yuan Zhu, Jinhua Deng, Xuhui Yang, Zhi Chen, Chunchun Huang, Shuxuan Chen, Lue Ma, Ying Lin, Weifeng Zhu, Feiqi |
| description | Background
There are no effective therapies to prevent the occurrence and progression of vertebrobasilar dolichoectasia (VBD). In this study, we investigated the relationship between serum levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) and the occurrence and progression of VBD.
Methods
Sixty (60) cases without VBD and ischemia stroke were considered as Group A, 100 cases with VBD were further divided into Group B (VBD without ischemic stroke,
n
= 54) and Group C (VBD with first ever acute posterior circulation ischemic stroke,
n
= 46). Demographic data (such as gender and age) and past medical history (such as hypertension, diabetes, and smoking history) were collected. The levels of serum low-density lipoprotein cholesterol (LDL-C), hypersensitivity C reactive protein (hs-CRP), glycosylated hemoglobin (HbAlc), homocysteine (HCY), uric acid (UA), fibrinogen (Fib), and Lp-PLA2, etc. were measured. Logistic regression analysis was used to assess the related factors of VBD and ischemic stroke secondary to VBD.
Results
Logistic multivariate regression analysis showed that only age and the level of serum Lp-PLA2 were significantly higher in group B than those in group A (
P
|
| doi_str_mv | 10.1007/s10072-020-04563-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2423056693</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2423056693</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-e3edeb9b0b1291e9f928e43bcdfe29c0d1d25b0dfd0f4cd7bc852890c188598f3</originalsourceid><addsrcrecordid>eNp9kcluFDEQhi0EImHgBTggS1y4NHjpxT5GUVikSByAc8tLdeLQ025c7ki8Cw9LDTOAxIGDF5W__6-Sf8aeS_FaCjG8wcOuGqFEI9qu183wgJ3LzopGt4N5eLpLM7Rn7AninRBCtlI_Zmda9a0RbX_OfnyCsu35DPcw8zzxOa15LblCWhqHmENyFSJfbzPSoleHwC8UT8gdX4lbanIz9ynvXfkK5eBxD6WCL9k7TLMrPJIu3GYIlQqOuyXyVJFTm5sCiCkvvGYeoJCIvNIyuRIqlZ-yR5ObEZ6dzh378vbq8-X75vrjuw-XF9dN0ENXG9AQwVsvvFRWgp2sMtBqH-IEygYRZVSdF3GKYmpDHHwwnTJWBGlMZ82kd-zV0ZdG-rYB1nGfMMA8uwXyhqNqlRZd31tN6Mt_0Lu8lYWmI8oo3dme4B1TRyqUjFhgGteS6IO-j1KMh9TGY3YjZTf-ym4cSPTiZL35PcQ_kt9hEaCPANLTcgPlb-__2P4EWvCovw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2482359642</pqid></control><display><type>article</type><title>Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Liu, Yuan ; Zhu, Jinhua ; Deng, Xuhui ; Yang, Zhi ; Chen, Chunchun ; Huang, Shuxuan ; Chen, Lue ; Ma, Ying ; Lin, Weifeng ; Zhu, Feiqi</creator><creatorcontrib>Liu, Yuan ; Zhu, Jinhua ; Deng, Xuhui ; Yang, Zhi ; Chen, Chunchun ; Huang, Shuxuan ; Chen, Lue ; Ma, Ying ; Lin, Weifeng ; Zhu, Feiqi</creatorcontrib><description>Background
There are no effective therapies to prevent the occurrence and progression of vertebrobasilar dolichoectasia (VBD). In this study, we investigated the relationship between serum levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) and the occurrence and progression of VBD.
Methods
Sixty (60) cases without VBD and ischemia stroke were considered as Group A, 100 cases with VBD were further divided into Group B (VBD without ischemic stroke,
n
= 54) and Group C (VBD with first ever acute posterior circulation ischemic stroke,
n
= 46). Demographic data (such as gender and age) and past medical history (such as hypertension, diabetes, and smoking history) were collected. The levels of serum low-density lipoprotein cholesterol (LDL-C), hypersensitivity C reactive protein (hs-CRP), glycosylated hemoglobin (HbAlc), homocysteine (HCY), uric acid (UA), fibrinogen (Fib), and Lp-PLA2, etc. were measured. Logistic regression analysis was used to assess the related factors of VBD and ischemic stroke secondary to VBD.
Results
Logistic multivariate regression analysis showed that only age and the level of serum Lp-PLA2 were significantly higher in group B than those in group A (
P
< 0.012,
P
< 0.001, respectively), however, only the level of serum Lp-PLA2 was significantly higher in group C than those in group B (
P
< 0.001).
Conclusions
The serum marker Lp-PLA2 is an independent risk factor for the occurrence of VBD and the progression of VBD to posterior circulation ischemic stroke. Whether intervening on atherosclerosis could prevent the occurrence and development of VBD needs to be further studied.</description><identifier>ISSN: 1590-1874</identifier><identifier>EISSN: 1590-3478</identifier><identifier>DOI: 10.1007/s10072-020-04563-7</identifier><identifier>PMID: 32648046</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>1-Alkyl-2-acetylglycerophosphocholine Esterase ; Arteriosclerosis ; Atherosclerosis ; Biomarkers ; Blood vessels ; C-reactive protein ; Cerebral Infarction ; Cerebrovascular diseases ; Cholesterol ; Diabetes mellitus ; Elongation ; Fibrinogen ; Hemoglobin ; Homocysteine ; Humans ; Hypersensitivity ; Ischemia ; Lipoproteins ; Low density lipoprotein ; Medicine ; Medicine & Public Health ; Neurology ; Neuroradiology ; Neurosciences ; Neurosurgery ; Original Article ; Phospholipase A2 ; Psychiatry ; Regression analysis ; Risk Factors ; Serum levels ; Stroke ; Uric acid ; Vertebrobasilar Insufficiency - diagnostic imaging</subject><ispartof>Neurological sciences, 2021-02, Vol.42 (2), p.599-605</ispartof><rights>Fondazione Società Italiana di Neurologia 2020</rights><rights>Fondazione Società Italiana di Neurologia 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-e3edeb9b0b1291e9f928e43bcdfe29c0d1d25b0dfd0f4cd7bc852890c188598f3</citedby><cites>FETCH-LOGICAL-c375t-e3edeb9b0b1291e9f928e43bcdfe29c0d1d25b0dfd0f4cd7bc852890c188598f3</cites><orcidid>0000-0003-4704-8928</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10072-020-04563-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10072-020-04563-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32648046$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Yuan</creatorcontrib><creatorcontrib>Zhu, Jinhua</creatorcontrib><creatorcontrib>Deng, Xuhui</creatorcontrib><creatorcontrib>Yang, Zhi</creatorcontrib><creatorcontrib>Chen, Chunchun</creatorcontrib><creatorcontrib>Huang, Shuxuan</creatorcontrib><creatorcontrib>Chen, Lue</creatorcontrib><creatorcontrib>Ma, Ying</creatorcontrib><creatorcontrib>Lin, Weifeng</creatorcontrib><creatorcontrib>Zhu, Feiqi</creatorcontrib><title>Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction</title><title>Neurological sciences</title><addtitle>Neurol Sci</addtitle><addtitle>Neurol Sci</addtitle><description>Background
There are no effective therapies to prevent the occurrence and progression of vertebrobasilar dolichoectasia (VBD). In this study, we investigated the relationship between serum levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) and the occurrence and progression of VBD.
Methods
Sixty (60) cases without VBD and ischemia stroke were considered as Group A, 100 cases with VBD were further divided into Group B (VBD without ischemic stroke,
n
= 54) and Group C (VBD with first ever acute posterior circulation ischemic stroke,
n
= 46). Demographic data (such as gender and age) and past medical history (such as hypertension, diabetes, and smoking history) were collected. The levels of serum low-density lipoprotein cholesterol (LDL-C), hypersensitivity C reactive protein (hs-CRP), glycosylated hemoglobin (HbAlc), homocysteine (HCY), uric acid (UA), fibrinogen (Fib), and Lp-PLA2, etc. were measured. Logistic regression analysis was used to assess the related factors of VBD and ischemic stroke secondary to VBD.
Results
Logistic multivariate regression analysis showed that only age and the level of serum Lp-PLA2 were significantly higher in group B than those in group A (
P
< 0.012,
P
< 0.001, respectively), however, only the level of serum Lp-PLA2 was significantly higher in group C than those in group B (
P
< 0.001).
Conclusions
The serum marker Lp-PLA2 is an independent risk factor for the occurrence of VBD and the progression of VBD to posterior circulation ischemic stroke. Whether intervening on atherosclerosis could prevent the occurrence and development of VBD needs to be further studied.</description><subject>1-Alkyl-2-acetylglycerophosphocholine Esterase</subject><subject>Arteriosclerosis</subject><subject>Atherosclerosis</subject><subject>Biomarkers</subject><subject>Blood vessels</subject><subject>C-reactive protein</subject><subject>Cerebral Infarction</subject><subject>Cerebrovascular diseases</subject><subject>Cholesterol</subject><subject>Diabetes mellitus</subject><subject>Elongation</subject><subject>Fibrinogen</subject><subject>Hemoglobin</subject><subject>Homocysteine</subject><subject>Humans</subject><subject>Hypersensitivity</subject><subject>Ischemia</subject><subject>Lipoproteins</subject><subject>Low density lipoprotein</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Neurosurgery</subject><subject>Original Article</subject><subject>Phospholipase A2</subject><subject>Psychiatry</subject><subject>Regression analysis</subject><subject>Risk Factors</subject><subject>Serum levels</subject><subject>Stroke</subject><subject>Uric acid</subject><subject>Vertebrobasilar Insufficiency - diagnostic imaging</subject><issn>1590-1874</issn><issn>1590-3478</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kcluFDEQhi0EImHgBTggS1y4NHjpxT5GUVikSByAc8tLdeLQ025c7ki8Cw9LDTOAxIGDF5W__6-Sf8aeS_FaCjG8wcOuGqFEI9qu183wgJ3LzopGt4N5eLpLM7Rn7AninRBCtlI_Zmda9a0RbX_OfnyCsu35DPcw8zzxOa15LblCWhqHmENyFSJfbzPSoleHwC8UT8gdX4lbanIz9ynvXfkK5eBxD6WCL9k7TLMrPJIu3GYIlQqOuyXyVJFTm5sCiCkvvGYeoJCIvNIyuRIqlZ-yR5ObEZ6dzh378vbq8-X75vrjuw-XF9dN0ENXG9AQwVsvvFRWgp2sMtBqH-IEygYRZVSdF3GKYmpDHHwwnTJWBGlMZ82kd-zV0ZdG-rYB1nGfMMA8uwXyhqNqlRZd31tN6Mt_0Lu8lYWmI8oo3dme4B1TRyqUjFhgGteS6IO-j1KMh9TGY3YjZTf-ym4cSPTiZL35PcQ_kt9hEaCPANLTcgPlb-__2P4EWvCovw</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Liu, Yuan</creator><creator>Zhu, Jinhua</creator><creator>Deng, Xuhui</creator><creator>Yang, Zhi</creator><creator>Chen, Chunchun</creator><creator>Huang, Shuxuan</creator><creator>Chen, Lue</creator><creator>Ma, Ying</creator><creator>Lin, Weifeng</creator><creator>Zhu, Feiqi</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4704-8928</orcidid></search><sort><creationdate>20210201</creationdate><title>Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction</title><author>Liu, Yuan ; Zhu, Jinhua ; Deng, Xuhui ; Yang, Zhi ; Chen, Chunchun ; Huang, Shuxuan ; Chen, Lue ; Ma, Ying ; Lin, Weifeng ; Zhu, Feiqi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-e3edeb9b0b1291e9f928e43bcdfe29c0d1d25b0dfd0f4cd7bc852890c188598f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>1-Alkyl-2-acetylglycerophosphocholine Esterase</topic><topic>Arteriosclerosis</topic><topic>Atherosclerosis</topic><topic>Biomarkers</topic><topic>Blood vessels</topic><topic>C-reactive protein</topic><topic>Cerebral Infarction</topic><topic>Cerebrovascular diseases</topic><topic>Cholesterol</topic><topic>Diabetes mellitus</topic><topic>Elongation</topic><topic>Fibrinogen</topic><topic>Hemoglobin</topic><topic>Homocysteine</topic><topic>Humans</topic><topic>Hypersensitivity</topic><topic>Ischemia</topic><topic>Lipoproteins</topic><topic>Low density lipoprotein</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Neurosurgery</topic><topic>Original Article</topic><topic>Phospholipase A2</topic><topic>Psychiatry</topic><topic>Regression analysis</topic><topic>Risk Factors</topic><topic>Serum levels</topic><topic>Stroke</topic><topic>Uric acid</topic><topic>Vertebrobasilar Insufficiency - diagnostic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Yuan</creatorcontrib><creatorcontrib>Zhu, Jinhua</creatorcontrib><creatorcontrib>Deng, Xuhui</creatorcontrib><creatorcontrib>Yang, Zhi</creatorcontrib><creatorcontrib>Chen, Chunchun</creatorcontrib><creatorcontrib>Huang, Shuxuan</creatorcontrib><creatorcontrib>Chen, Lue</creatorcontrib><creatorcontrib>Ma, Ying</creatorcontrib><creatorcontrib>Lin, Weifeng</creatorcontrib><creatorcontrib>Zhu, Feiqi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Yuan</au><au>Zhu, Jinhua</au><au>Deng, Xuhui</au><au>Yang, Zhi</au><au>Chen, Chunchun</au><au>Huang, Shuxuan</au><au>Chen, Lue</au><au>Ma, Ying</au><au>Lin, Weifeng</au><au>Zhu, Feiqi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction</atitle><jtitle>Neurological sciences</jtitle><stitle>Neurol Sci</stitle><addtitle>Neurol Sci</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>42</volume><issue>2</issue><spage>599</spage><epage>605</epage><pages>599-605</pages><issn>1590-1874</issn><eissn>1590-3478</eissn><abstract>Background
There are no effective therapies to prevent the occurrence and progression of vertebrobasilar dolichoectasia (VBD). In this study, we investigated the relationship between serum levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) and the occurrence and progression of VBD.
Methods
Sixty (60) cases without VBD and ischemia stroke were considered as Group A, 100 cases with VBD were further divided into Group B (VBD without ischemic stroke,
n
= 54) and Group C (VBD with first ever acute posterior circulation ischemic stroke,
n
= 46). Demographic data (such as gender and age) and past medical history (such as hypertension, diabetes, and smoking history) were collected. The levels of serum low-density lipoprotein cholesterol (LDL-C), hypersensitivity C reactive protein (hs-CRP), glycosylated hemoglobin (HbAlc), homocysteine (HCY), uric acid (UA), fibrinogen (Fib), and Lp-PLA2, etc. were measured. Logistic regression analysis was used to assess the related factors of VBD and ischemic stroke secondary to VBD.
Results
Logistic multivariate regression analysis showed that only age and the level of serum Lp-PLA2 were significantly higher in group B than those in group A (
P
< 0.012,
P
< 0.001, respectively), however, only the level of serum Lp-PLA2 was significantly higher in group C than those in group B (
P
< 0.001).
Conclusions
The serum marker Lp-PLA2 is an independent risk factor for the occurrence of VBD and the progression of VBD to posterior circulation ischemic stroke. Whether intervening on atherosclerosis could prevent the occurrence and development of VBD needs to be further studied.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32648046</pmid><doi>10.1007/s10072-020-04563-7</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-4704-8928</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1590-1874 |
| ispartof | Neurological sciences, 2021-02, Vol.42 (2), p.599-605 |
| issn | 1590-1874 1590-3478 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2423056693 |
| source | MEDLINE; SpringerNature Journals |
| subjects | 1-Alkyl-2-acetylglycerophosphocholine Esterase Arteriosclerosis Atherosclerosis Biomarkers Blood vessels C-reactive protein Cerebral Infarction Cerebrovascular diseases Cholesterol Diabetes mellitus Elongation Fibrinogen Hemoglobin Homocysteine Humans Hypersensitivity Ischemia Lipoproteins Low density lipoprotein Medicine Medicine & Public Health Neurology Neuroradiology Neurosciences Neurosurgery Original Article Phospholipase A2 Psychiatry Regression analysis Risk Factors Serum levels Stroke Uric acid Vertebrobasilar Insufficiency - diagnostic imaging |
| title | Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A23%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20level%20of%20lipoprotein-associated%20phospholipase%20A2%20is%20a%20potential%20biomarker%20of%20vertebrobasilar%20dolichoectasia%20and%20its%20progression%20to%20cerebral%20infarction&rft.jtitle=Neurological%20sciences&rft.au=Liu,%20Yuan&rft.date=2021-02-01&rft.volume=42&rft.issue=2&rft.spage=599&rft.epage=605&rft.pages=599-605&rft.issn=1590-1874&rft.eissn=1590-3478&rft_id=info:doi/10.1007/s10072-020-04563-7&rft_dat=%3Cproquest_cross%3E2423056693%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2482359642&rft_id=info:pmid/32648046&rfr_iscdi=true |